Skip to main content

Advertisement

SpringerLink
Log in

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives

  • Feature … Practice of Immuno-Cell Therapy and its Future Prospect …
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Effective adoptive cancer immunotherapy depends on an ability to generate tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to deliver these effector cells to the tumor. Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of sensitizing T cells to new and recall antigens. Many studies have shown that tumors express unique proteins that can be loaded on DCs to lrigger an immune response. The current experimental and clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and vaccine-primed activated T cells are summarized herein. Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. These studies have shown that antigen-loaded DC vaccination is safe and promising for the treatment of cancer. In addition, tumor vaccine-primed T cells have been shown to induce antitumor activity in vivo. Several clinical studies are being conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. It is reasonable to consider using both tumor antigen-pulsed DCs and vaccine-primed lymphocytes as adjuvants. We are now investigating the use of autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated lymphocytes in patients with multiple metastasis of solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245–252, 1998.

    Article  PubMed  CAS  Google Scholar 

  2. Young JW and Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med. 183: 7–11, 1996.

    Article  PubMed  CAS  Google Scholar 

  3. Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245–273, 2000.

    Article  PubMed  CAS  Google Scholar 

  4. Nestle FO, Banchereau J and Hart D: Dendritic cell: On the move from bench to bedside Nat Med 7: 761–765, 2001

    Article  PubMed  CAS  Google Scholar 

  5. Steinman RM and Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94: 459–473, 2001.

    Article  PubMed  CAS  Google Scholar 

  6. Celluzzi CM, Mayordomo JI, Storkus WJ, et al.: Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 183: 283–287, 1996.

    Article  PubMed  CAS  Google Scholar 

  7. Boczkowski D, Nair SK, Snyder D, et al.: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465–472, 1996

    Article  PubMed  CAS  Google Scholar 

  8. Fields RC, Shimizu K and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95: 9482–9487, 1998.

    Article  PubMed  CAS  Google Scholar 

  9. Geiger J, Hutchinson R, Hohenkirk L, et al.: Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356: 1163–1165, 2000.

    Article  PubMed  CAS  Google Scholar 

  10. Nair SK, Boczkowski D, Snyder D, et al.: Anitgen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27: 589–597, 1997.

    Article  PubMed  CAS  Google Scholar 

  11. Yee C, Thompson JA, Byrd D, et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistance, migration, and antitumor effect of transferred T cells. Proc. Acad Natl. Sci. 99: 16168–16173, 2002.

    Article  CAS  Google Scholar 

  12. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immuneotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356: 802–807, 2000.

    Article  PubMed  CAS  Google Scholar 

  13. Zitvogel L, Mayordomo JI, Tjandrawan T, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183: 87–97, 1996.

    Article  PubMed  CAS  Google Scholar 

  14. Gerosa F, Baldani-Guerra B, Nissi C, et al.: Reciprocal activating interaction between NK cells and dendritic cells. J. Exp. Med. 195: 327–333, 2002.

    Article  PubMed  CAS  Google Scholar 

  15. Felazzo G, Tsang ML, Moretta L, et al.: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp. Med. 195: 343–351, 2002.

    Article  Google Scholar 

  16. Fernandez NC, Lozier A, Flament P, et al.: Dendritic cells directly trigger NK cell functions: a cross-talk relevant in innate antitumor immune responses in vivo. Nat. Med.. 5: 405–411, 1999.

    Article  PubMed  CAS  Google Scholar 

  17. Mailliard RB and Lotze M: Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor target. Clin Cancer Res 7: 980–988, 2001.

    Google Scholar 

  18. Hsu FFJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 2: 52–58, 1996.

    Article  PubMed  CAS  Google Scholar 

  19. Liau LM, Black KL, Prins RM, et al.: Treatment of intracranial gliomas with tumor antigens. J Neurosurg. 90 1115–1124, 1999.

    Article  PubMed  CAS  Google Scholar 

  20. Nair SK, Boczkowski D, Snyder D, et al.: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27: 589–597, 1997.

    Article  PubMed  CAS  Google Scholar 

  21. Jenne L, Anighi JF, Jonuleit H, et al.: Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 60: 4446–4452, 2000.

    PubMed  CAS  Google Scholar 

  22. Thurner B, Haendle I, Roder C, et al.: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastasis in advanced stage IV melanoma. J Exp. Met 190: 1669–1678, 1999.

    Article  CAS  Google Scholar 

  23. Sadanaga N, Nagashima H, Mashino K, et al.: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7 2277–2284, 2001.

    PubMed  CAS  Google Scholar 

  24. Morse MA, Deng Y, Coleman D, et al.: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5: 1331–1338, 1999.

    PubMed  CAS  Google Scholar 

  25. Heiser A, Coleman D, Dannull J, et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses aganinst metastatic prostate tumors. J Clin Invest 109 409–417, 2002.

    PubMed  CAS  Google Scholar 

  26. Regnault A, Lankar D, Lacabanne V, et al.: Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 189: 371–380, 1999.

    Article  PubMed  CAS  Google Scholar 

  27. Castellino F, Boucher PE, Eichelberg K, et al.: Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med. 191: 1957–1964, 2000.

    Article  PubMed  CAS  Google Scholar 

  28. Gallucci S, Lolkema M and Matzinger P Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5: 1249–1255, 1999.

    Article  PubMed  CAS  Google Scholar 

  29. Sauter B, Albert ML, Francisco L, et al.: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423–434, 2000.

    Article  PubMed  CAS  Google Scholar 

  30. Steinman RM, Turley S, Mellman I, et al.: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411–416, 2000.

    Article  PubMed  CAS  Google Scholar 

  31. Dhodapkar MV, Steinman RM, Sapp M, et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104: 173–180, 1999.

    Article  PubMed  CAS  Google Scholar 

  32. Schuler-Thurner B, Schultz ES, Berger TG, et al.: Rapid induction of tumor specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195: 12791288, 2002.

    Article  Google Scholar 

  33. Dhodapkar MV and Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 100: 174–177, 2002.

    Article  PubMed  CAS  Google Scholar 

  34. Kuroki H, Morisaki T, Matsumoto K, et al.: Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 52: 561–568, 2003.

    Article  PubMed  CAS  Google Scholar 

  35. Hsu FJ, Benike C, Fagnone F, et al.: Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58, 1996.

    Article  PubMed  CAS  Google Scholar 

  36. Liso A, Stockerl-Goldstein KE, Aufferman-Gretzinger S, et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 6: 621–627, 2000.

    Article  PubMed  CAS  Google Scholar 

  37. Fong L, Brockstdt D, Benike, Breen JK, et al.: Dendritic cell-based xenoantigen vaccination to prostate cancer immunotherapy. J. Immunol 167: 7150–7156, 2001.

    PubMed  CAS  Google Scholar 

  38. Nestle FO, Alijagic S, Gilliert M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 4: 328–332, 1998.

    Article  PubMed  CAS  Google Scholar 

  39. O’Rouke MG, Johnson M, Lanagan C, et al.: Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 52: 387–395, 2003.

    Google Scholar 

  40. Märten A, Flieger D, Renoth S, et al.: Therapeutic vaccination against metastatic renal carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51: 637–644, 2002.

    Article  PubMed  Google Scholar 

  41. Burch PA, Breen JK, Buckner JC, et al.: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 6: 2175–2182, 2000.

    PubMed  CAS  Google Scholar 

  42. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al.: Vaccination of pediatric solid tumor patinents with tumor-lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61: 8513–8519, 2001.

    PubMed  CAS  Google Scholar 

  43. Hernando JJ, Park T-W, Kubler K, et al.: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunothr 51: 45–52, 2002.

    Article  CAS  Google Scholar 

  44. Chang AE, Redman BG, Whitfield JR, et al.: A pahse I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8: 1021–1032, 2002.

    PubMed  CAS  Google Scholar 

  45. Shift A, Fried1 J, Dubsky P, et al.: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135–142, 2003.

    Article  Google Scholar 

  46. Holtl L, Zelle-Rieser C, Gander H, et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res 8: 3369–3376, 2002.

    PubMed  CAS  Google Scholar 

  47. Chang AE, Li Q, Jiang G, et al.: Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head & Neck 25 198–209, 2003.

    Article  Google Scholar 

  48. Meijer SL, Dols A, Urba WJ, et al.: Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologopus tumor cells. J Immnuother. 25: 359–372, 2002.

    Article  CAS  Google Scholar 

  49. Morisaki T, Mastumoto K, Kuroki H, et al.: Combined immunotherapy with intracavital injection of activated lymphocytes and monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion. Anticancer Res. 23: 4459–4466, 2003.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, 812-8582, Fukuoka, Japan

    Takashi Morisaki, Kotaro Matsumoto, Hideya Onishi, Hideo Kuroki, Eishi Baba, Akira Tasaki, Makoto Kubo & Mitsuo Katano

  2. Sada Hospital, Fukuoka, Japan

    Mitsunari Nakamura

  3. Blood Transfusion Services, Kyushu University Hospital, Fukuoka, Japan

    Syoichi Inaba

  4. Department of Clinical Oncology and Surgery Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Koji Yamaguchi & Masao Tanaka

Authors
  1. Takashi Morisaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kotaro Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideya Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideo Kuroki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eishi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Tasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Makoto Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsunari Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Syoichi Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Koji Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masao Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mitsuo Katano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morisaki, T., Matsumoto, K., Onishi, H. et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16, 175–182 (2003). https://doi.org/10.1111/j.1749-0774.2003.tb00151.x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1749-0774.2003.tb00151.x

Key words

Search

Navigation